RT Journal Article
SR Electronic
T1 A genome-wide association study for nonalcoholic fatty liver disease identifies novel genetic loci and trait-relevant candidate genes in the Million Veteran Program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.26.20248491
DO 10.1101/2020.12.26.20248491
A1 Vujkovic, Marijana
A1 Ramdas, Shweta
A1 Lorenz, Kimberly M.
A1 Schneider, Carolin V.
A1 Park, Joseph
A1 Lee, Kyung M.
A1 Serper, Marina
A1 Carr, Rotonya M.
A1 Kaplan, David E.
A1 Haas, Mary E.
A1 MacLean, Matthew T.
A1 Witschey, Walter R.
A1 Zhu, Xiang
A1 Tcheandjieu, Catherine
A1 Kember, Rachel L.
A1 Kranzler, Henry R.
A1 Verma, Anurag
A1 Giri, Ayush
A1 Klarin, Derek M.
A1 Sun, Yan V.
A1 Huang, Jie
A1 Huffman, Jennifer
A1 Creasy, Kate Townsend
A1 Hand, Nicholas J.
A1 Liu, Ching-Ti
A1 Long, Michelle T.
A1 Rotter, Jerome I.
A1 Guo, Xiuqing
A1 Yao, Jie
A1 Budoff, Matthew
A1 Ryan, Katherine A.
A1 Mitchell, Braxton D.
A1 Gill, Dipender
A1 Wells, Andrew D.
A1 Manduchi, Elisabetta
A1 Saiman, Yedidya
A1 Mahmud, Nadim
A1 Miller, Donald R.
A1 Reaven, Peter D.
A1 Phillips, Laurence S.
A1 Muralidhar, Sumitra
A1 DuVall, Scott L.
A1 Lee, Jennifer S.
A1 Assimes, Themistocles L.
A1 Pyarajan, Saiju
A1 Cho, Kelly
A1 Edwards, Todd L.
A1 Damrauer, Scott M.
A1 Wilson, Peter W.
A1 Gaziano, John M.
A1 O’Donnell, Christopher J.
A1 Khera, Amit V.
A1 Grant, Struan F.A.
A1 Brown, Christopher D.
A1 Tsao, Philip S.
A1 Saleheen, Danish
A1 Meigs, James B.
A1 Lynch, Julie A.
A1 Rader, Daniel J.
A1 Voight, Benjamin F.
A1 Chang, Kyong-Mi
YR 2021
UL http://medrxiv.org/content/early/2021/01/02/2020.12.26.20248491.abstract
AB Nonalcoholic fatty liver disease (NAFLD) is a prevalent, heritable trait that can progress to cancer and liver failure. Using our recently developed proxy definition for NAFLD based on chronic liver enzyme elevation without other causes of liver disease or alcohol misuse, we performed a multi-ancestry genome-wide association study in the Million Veteran Program with 90,408 NAFLD cases and 128,187 controls. Seventy-seven loci exceeded genome-wide significance of which 70 were novel, with an additional European-American specific and two African-American specific loci. Twelve of these loci were also significantly associated with quantitative hepatic fat on radiological imaging (n=44,289). Gene prioritization based on coding annotations, gene expression from GTEx, and functional genomic annotation identified candidate genes at 97% of loci. At eight loci, the allele associated with lower gene expression in liver was also associated with reduced risk of NAFLD, suggesting potential therapeutic relevance. Functional genomic annotation and gene-set enrichment demonstrated that associated loci were relevant to liver biology. We expand the catalog of genes influencing NAFLD, and provide a novel resource to understand its disease initiation, progression and therapy.Competing Interest StatementH.R.K. is a member of a Dicerna scientific advisory board, a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka, and is named as an inventor on PCT patent application 15/878,640 entitled ‘Genotype-guided dosing of opioid agonists,’ filed January 24, 2018.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration and was supported by award no. MVP000. This publication does not represent the views of the Department of Veterans Affairs, the US Food and Drug Administration, or the US Government. This research was also supported by funding from: the Department of Veterans Affairs awards I01- BX003362 (P.S.T. and K.M.C) and I01BX003341 (H.R.K. Co-Principal Investigator) and the VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 130457 (S.L.D). B.F.V. acknowledges support for this work from the NIH/NIDDK (DK101478 and DK126194) and a Linda Pechenik Montague Investigator award. K.M.C, S.M.D, J.M.G, C.J.O, L.S.P, and P.S.T. are supported by the VA Cooperative Studies Program. S.M.D. is supported by the Veterans Administration [IK2 CX001780]. Funding support is also acknowledged for MS (K23 DK115897), R.M.C (R01 AA026302), D.K. (National Heart, Lung, and Blood Institute of the National Institutes of Health [T32 HL007734]), L.S.P. (VA awards I01 CX001025, and I01 CX001737, NIH awards R21 DK099716, U01 DK091958, U01 DK098246, P30 DK111024, and R03 AI133172, and a Cystic Fibrosis Foundation award PHILLI12A0). The Rader lab was supported by NIH grants HL134853 (NJH and DJR) and DK114291-01A1 (K.T.C, N.J.H, and D.J.R). We thank all study participants for their contribution. Support for imaging studies was provided by ITMAT (NIH NCATS UL1TR001878), the Penn Center for Precision Medicine Accelerator Fund and R01 HL137501. Data for external replication and hepatic fat concordance were provided by investigators using United Kingdom BioBank, Multi-Ethnic Study of Atherosclerosis (MESA), Old Order Amish Study (Amish), Framingham Heart Study (FHS) and Penn Medicine Biobank (PMBB). MESA/MESA SHARe Acknowledgements: MESA and the MESA SHARe projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. This research was supported by R01 HL071739 and MESA was supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. Also supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies have received ethical and study protocol approval from their respective institutional review boards (IRBs) in accordance with the principles outlined in the Declaration of Helsinki.The Million Veteran Program (MVP) received approval it's study protocol by the Veterans Affairs Central IRB, and by the IRBs at each field center where all participants gave written informed consent. All local R&D IRB committees are: Corporal Michael J. Crescenz VA Medical Center; VA Palo Alto Health Care System; VA Salt Lake City Health Care System; Edith Nourse Rogers Memorial Veterans Hospital; Phoenix VA Health Care System; Atlanta VA Medical Center; VA Boston Healthcare System; and the North Florida / South Georgia Veterans Health System.The study protocol for the Penn Medicine Biobank (PMBB) was approved by the IRB of the University of Pennsylvania. Informed consent was obtained from each study participant.The study protocol for the Older Order Amish study was approved by the IRB at the University of Maryland Baltimore. Informed consent was obtained from each study participant.The Framingham Heart Study (FHS) study protocol was approved by the IRB of the Boston University Medical Center. All study participants provided written informed consent.All participants of the Multi-Ethnic Study of Atherosclerosis (MESA) provided written informed consent, and the study was approved by the IRBs at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University.The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference number 11/NW/0382). Use of UK Biobank data (application 7089) was approved by the local Mass General Brigham IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full summary level association data from the trans-ancestry, European, African American, Hispanic, and Asian meta-analysis from this report will be available through dbGAP project number phs001672.v4.p1 (study-specific accession codes will be available before publication). https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/analysis.cgi?study_id=phs001672.v4.p1